ubenimex has been researched along with Cancer of Liver in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J; Huang, Y; Li, Y; Liang, X; Ma, C; Wu, P; Xu, W; Zhang, Y | 1 |
| Cao, J; Ding, Q; Gao, Q; Gao, S; Kong, X; Liang, X; Ma, C; Wang, B; Xu, W; Yan, Y; Zang, J; Zhang, Y; Zhao, C | 1 |
| Hou, X; Jia, G; Jiang, Y; Li, P; Li, X; Tan, L; Wang, X; Xu, W; Yue, K; Zhang, J; Zhang, L; Zhang, Z | 1 |
| Dou, C; Fang, C; Fu, X; Li, D; Liu, H; Liu, Z; Wang, H; Wang, X; Wu, H; Xu, W; Zhang, J; Zhang, Y; Zhao, Y; Zhu, D | 1 |
| Li, Y; Liu, XJ; Wu, SY; Zhen, YS; Zheng, YB | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Kawamoto, K; Mori, M; Noda, T; Ogawa, H; Umeshita, K; Wada, H; Yamada, D; Yamashita, M | 1 |
6 other study(ies) available for ubenimex and Cancer of Liver
| Article | Year |
|---|---|
Novel leucine ureido derivatives as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.
Topics: Animals; Antineoplastic Agents; CD13 Antigens; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Leucine; Liver Neoplasms; Lung Neoplasms; Mice; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship | 2016 |
Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.
Topics: Animals; Antineoplastic Agents; Binding Sites; CD13 Antigens; Cell Line, Tumor; Cell Proliferation; Click Chemistry; Disease Models, Animal; Human Umbilical Vein Endothelial Cells; Humans; Leucine; Liver Neoplasms; Lung Neoplasms; Mice; Molecular Docking Simulation; Neovascularization, Physiologic; Protease Inhibitors; Protein Structure, Tertiary; Structure-Activity Relationship | 2018 |
Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Leucine; Liver Neoplasms; Molecular Structure; Structure-Activity Relationship | 2021 |
BC-02 eradicates liver cancer stem cells by upregulating the ROS-dependent DNA damage.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; DNA Damage; Female; Fluorouracil; Humans; Leucine; Liver Neoplasms; Mice; Mice, Nude; Neoplastic Stem Cells; Reactive Oxygen Species; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
A multifunctional drug combination shows highly potent therapeutic efficacy against human cancer xenografts in athymic mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Dexamethasone; Dipyridamole; Electrophoresis, Gel, Two-Dimensional; Female; Humans; Leucine; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured; Tumor Microenvironment; Vasodilator Agents; Xenograft Model Antitumor Assays | 2014 |
A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; CD13 Antigens; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Leucine; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib | 2016 |